Zogenix reports additional Phase III data for ZX008 in Dravet syndrome

Zogenix Inc. (NASDAQ:ZGNX) reported additional data from the Phase III Study 1 to treat Dravet syndrome showing that once-daily 0.8 mg/kg ZX008 as adjunctive therapy led to a “much improved” or “very much improved” overall condition rating on the Clinical Global Impression of Change (CGI-C) in 55% of patients according to parents/caregivers and 62.5% of patients according to investigators vs. 10% of patients receiving placebo according to both parents/caregivers and investigators (p=0.001 for both). Data were presented at the American Epilepsy Society meeting in Washington D.C.

Zogenix previously reported that ZX008 met the trial’s primary endpoint of reducing mean monthly convulsive seizure frequency from baseline to week 14. The trial also evaluated a once-daily 0.2 mg/kg dose of ZX008 (see BioCentury, Oct. 6)...